申请人:Tianjin Taipu Pharmaceutical Science & Technology
Development Co., Ltd.
公开号:EP2474522A1
公开(公告)日:2012-07-11
Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-Kα and showed by 20(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern has characteristic absorption peaks at about 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm-1; and its DSC endothermic transition temperature is 97.6°C. The use of the agomelatine crystal as an active ingredient in preparing a medicament for the treatment of depression is also provided.
本研究提供了治疗抑郁症的药物阿戈美拉汀晶体及其药物组合物。这种阿戈美拉汀晶体经Cu-Kα辐照后,其X射线粉末衍射谱图在20(度)处有特征衍射峰,分别为12.84、13.84、16.14、18.56、19.12、20.86、21.20、23.84;其红外吸收图谱在约3234、3060、2940、1638、1511、1436、1249、1215、1184、1032、908、828、755、588 cm-1处有特征吸收峰;其DSC内热转变温度为97.6℃。还提供了阿戈美拉汀晶体作为活性成分在制备治疗抑郁症药物中的用途。